Rhumbline Advisers Dyne Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 154,541 shares of DYN stock, worth $2.16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
154,541
Previous 133,627
15.65%
Holding current value
$2.16 Million
Previous $1.4 Million
5.3%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding DYN
# of Institutions
211Shares Held
122MCall Options Held
36.5KPut Options Held
74.3K-
Ra Capital Management, L.P. Boston, MA9.71MShares$136 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$132 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$127 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$107 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$103 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $722M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...